COPD Flow Sheet
COPD Flow Sheet
COPD Flow Sheet
COPD
Ensure diagnosis of COPD was made with Pre & Post Spirometry testing and meets both the following Canadian Thoracic Societies criteria to establish a diagnosis of COPD: Post bronchodilator FEV1.0/FVC ratio < 0.7, and a post bronchodilator FEV1.0 < 80% predicted
Too SOB to leave the house, or SOB when dressing (If yes, MRC score of grade 5= severe stage of COPD)
REVIEW ITEMS
DATE:
C O PD S EV ER I T Y
Stops for breath after walking about 100 yards (If yes, MRC score of grade 4= moderate stage of COPD)
Walks slower than people of same age on the level, or stops for breath while walking at own pace on the level (If yes, MRC score of grade 3 = moderate stage of COPD)
SOB when hurrying on a level surface or walking up slight hill (If yes, MRC score of grade 2 = mild stage of COPD)
SOB with strenuous exercise (If yes, MRC score of grade 1 = very mild stage of COPD) MRC = medical research council dyspnea scale, which is recommended by the CTS for assessment of disability from COPD Temperature, pulse, respirations, blood pressure (PRN)
FOR
COPD
Auscultation q visit
VISITS
PHYSICAL EXAM
OFFICE
Poor nutritional status (BMI, low <18.5 or high > 24.9) (Note: if over 65 years BMI, low < 24.0 or high > 29.0)
Clinical signs of depression/anxiety Atypical features of COPD: Early onset of COPD (< 40 years) Family Hx of COPD Disabled in 40s or 50s from COPD If present, arrange screening for AAT deficiency
RE G ULA R
M A N A GEM EN T
ANNUALLY OR AS NEEDED
Blood work
TESTS
OTHER
Atypical features of COPD present, write the following on a CHR lab req: Alpha-1 antitrypsin Pi phenotype test
Sputum gram stain & culture when purulent AECOPD if: very poor lung function, AECOPD > 3/year or has been on antibiotics in last 3 months Bone Mineral Density (BMD) for osteoporosis (If on ICS/oral steroids and has risk factors) Referrals: COPD educator/program for education & pulmonary Rehab Pulmonary Medical Specialist- as needed Vaccinations: Annual influenza vaccine Pneumococcal vaccine (once in lifetime, repeat in 5-10 years in high risk patients)
Revised as of June 16, 2005 developed by the BHL/ chronic respiratory/ Chinook Health Region
11
COPD
COPD
With frequent AECOPD (> 3/year) add in ICSs to a long acting bronchodilators in a combination product + a long acting anticholinergic medication
Without frequent AECOPD ( < 3/year) long-acting bronchodilators + long-acting anticholinergic medications
Add long-acting bronchodilator or a long-acting anticholinergic medication and refer to a pulmonary rehabilitation program
Add Short-acting Bronchodilator as needed Smoking cessation, encourage healthy lifestyle, activity & Patient education Annual Influenza vaccination, Pneumococcal vaccination (If diagnosed with COPD once in lifetime) SOB from COPD SOB from COPD Over 40 years SOB from COPD resulting in the when hurrying on causing the patient client too breathless to leave the house, Smoker or an to stop walking ex-smoker the level or or breathless after dressing/undressing Asymptomatic or walking up a after a few minutes or the presence of chronic respiratory chronic cough or slight hill on the level failure or clinical signs of right heart SOB with exertion failure.
For symptomatic or rescue treatment Salbutamol (Ventolin) MDI/spacer 100 mcg per dose 1 or 2 inhalations QID and prn Salbutamol (Ventolin) Diskus 200 mcg per dose 1 inhalation QID and prn Combivent (salbutamol 120 mcg/ipratropium 20 mcg per dose) MDI/spacer 2 inhalations QID and prn Ipratropium (Atrovent) MDI/spacer 20 mcg per dose 2 inhalations QID and prn Terbutaline (Bricanyl) turbuhaler 0.5 mg per dose 1 inhalation QID and prn Salbutamol (Airomir) MDI/spacer 100 mcg per dose 1 or 2 inhalations QID and prn
Short-acting Bronchodilators
Grade 0
Grade 1-2
Grade 3 4
Grade 5
Stages of COPD
AT RISK
MILD
MODERATE
SEVERE
Can be used alone or in a combination product Salmeterol (Serevent) MDI/spacer 25 mcg per dose 1 or 2 inhalations BID Salmeterol (Serevent) Diskus 50 mcg per dose 1 inhalation BID Formoterol (Oxeze) Turbuhaler 6 or 12 mcg per dose 1 to 2 inhalations BID of 6 mcg dose 1 inhalation BID of 12 mcg dose
Tiotropium (Spiriva) Handihaler 18 mcg per dose 1 inhalation QD***
14
Recommended for severe COPD with > than 3 exacerbations per year, use LABA and ICS in combination form: Building Healthy Lifestyles Symbicort (Oxeze 6 mcg/pulmicort 100 or 200 mcg per dose) Turbuhaler 1 or 2 inhalations BID Advair (Serevent 25 mcg/flovent 125 or 250 mcg per dose) MDI/spacer 1 or 2 inhalations BID Advair (Serevent 50 mcg/flovent 100, 200 or 500 mcg per dose) Diskus 1 inhalation BID
*** Spiriva is not to be used in conjunction with Atrovent or Combivent inhalers. Treatment options from the 2003 Canadian Thoracic Society Recommendations for Management of COPD Medication information updated as of May 9, 2005
Inhaled bronchodilators to treat dyspnea in AECOPD consider combination therapy (Combivent MDI/spacer) No role for the initiation of methylxanthines during AECOPD, possible drug interactions with antibiotics. Oral/parenteral steroids for 14 days in most moderate to severe clients with COPD, limited data on benefits of clients with mild COPD (FEV1.0 > 60% of predicted). Dosages of 25 to 50 mg per day are recommended. Antibiotic therapy is recommended only for those clients with purulent exacerbations, refer to chart below:
12